Published in Nat Med on January 01, 1996
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A (1998) 3.23
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol (1998) 2.11
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
p53 activity and chemotherapy. Nat Med (1996) 1.53
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A (2004) 1.42
Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A (2000) 1.38
Treating breast cancer before surgery. BMJ (1996) 1.38
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene (2008) 1.37
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. Front Oncol (2014) 1.33
Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol (1997) 1.28
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A (1997) 1.24
DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci U S A (1996) 1.22
Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. J Cell Biol (2003) 1.22
p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (1997) 1.21
Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A (1999) 1.20
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer (2011) 1.18
Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol (2003) 1.17
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis (2013) 1.13
Anti-apoptotic activity of low levels of wild-type p53. EMBO J (1996) 1.13
Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol (2005) 1.12
The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev (2004) 1.11
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer (1998) 1.11
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A (1998) 1.08
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene (2014) 1.08
Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol (1996) 1.08
p53 suppresses structural chromosome instability after mitotic arrest in human cells. Oncogene (2010) 1.05
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One (2011) 1.03
Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev (2006) 1.02
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia (2001) 1.00
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability. Proc Natl Acad Sci U S A (2007) 0.97
Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer (1998) 0.97
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A (1998) 0.94
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 0.94
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer (1998) 0.93
miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. PLoS One (2014) 0.93
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res (2011) 0.91
Triple-negative breast cancer. Wien Med Wochenschr (2010) 0.91
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res (2012) 0.90
Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer (1997) 0.90
Persistent mitochondrial hyperfusion promotes G2/M accumulation and caspase-dependent cell death. PLoS One (2014) 0.89
Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis. J Cell Biol (2001) 0.89
Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res (2004) 0.89
c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer (1999) 0.89
The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol (2011) 0.89
Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer (1998) 0.89
Overexpression of simian virus 40 small-T antigen blocks centrosome function and mitotic progression in human fibroblasts. J Virol (2001) 0.88
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer (2002) 0.88
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer (1998) 0.88
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer (2006) 0.87
Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology (1998) 0.86
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer (2004) 0.86
Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer (2001) 0.86
Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res (2011) 0.85
Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One (2014) 0.85
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res (2001) 0.84
Soft tissue sarcomas and p53 mutations. Mol Med (1998) 0.83
Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer (2003) 0.83
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther (2013) 0.83
Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer (1998) 0.83
Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer (2001) 0.83
Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage. Stem Cell Reports (2015) 0.82
Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncol (2009) 0.82
A new isoquinolinium derivative, Cadein1, preferentially induces apoptosis in p53-defective cancer cells with functional mismatch repair via a p38-dependent pathway. J Biol Chem (2009) 0.82
Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int J Mol Sci (2013) 0.82
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs (2000) 0.81
Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Cancer Med (2012) 0.80
Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures. Biotechnol Bioeng (2014) 0.80
An image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells. Mol Cancer Res (2011) 0.80
p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol (2003) 0.80
Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer (1998) 0.80
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget (2016) 0.79
Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress. Br J Cancer (2003) 0.79
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer (2006) 0.78
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget (2015) 0.78
Carcinogenic effects of ptaquiloside in bracken fern and related compounds. Br J Cancer (2000) 0.78
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. Neoplasia (2000) 0.78
Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. BMC Cancer (2011) 0.77
p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer (2002) 0.77
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol (2013) 0.77
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines. Front Oncol (2011) 0.77
pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine (2012) 0.77
Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol (2007) 0.77
The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci (2016) 0.77
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. PLoS One (2014) 0.76
The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo. PLoS One (2015) 0.76
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res Treat (2017) 0.75
Swearing off the oath? J R Soc Med (1997) 0.75
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst (1998) 4.42
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65
Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature (1996) 3.61
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol (1992) 2.61
YC-1, a novel activator of platelet guanylate cyclase. Blood (1994) 2.38
Chondroblastoma of bone. J Bone Joint Surg Am (2000) 2.33
The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature (1983) 2.26
Detection of herpes simplex RNA in human sensory ganglia. Virology (1979) 2.23
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol (2001) 2.18
Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia. J Virol (1982) 2.12
Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J Hepatol (1995) 2.10
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A (1994) 2.02
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 1.93
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol (1995) 1.87
Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol (1998) 1.84
Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res (1998) 1.83
Genital human papillomavirus infection in women who have sex with women. J Infect Dis (1998) 1.77
Evidence of prevalent genital-type human papillomavirus infections in adults and children. J Infect Dis (1990) 1.74
Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol (2001) 1.74
Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst (1997) 1.72
Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene (1996) 1.71
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1983) 1.70
Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol (2001) 1.66
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med (1998) 1.61
Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart. J Virol (1985) 1.60
Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res (1995) 1.59
E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol (2001) 1.58
Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol (1996) 1.57
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J (2008) 1.55
Sequence and structural requirements of a herpes simplex viral DNA replication origin. Mol Cell Biol (1988) 1.55
Endoscopic injection for the treatment of bleeding ulcers: local tamponade or drug effect? Endoscopy (1994) 1.54
Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J Virol (1981) 1.54
Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol (1988) 1.51
The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol (1989) 1.47
Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology (1992) 1.45
Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. Proc Natl Acad Sci U S A (1998) 1.44
Cloning and characterization of oriL2, a large palindromic DNA replication origin of herpes simplex virus type 2. J Virol (1986) 1.44
Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension. J Hepatol (1999) 1.43
Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem (1996) 1.43
Sequential variceal pressure measurement by endoscopic needle puncture during maintenance sclerotherapy: the correlation between variceal pressure and variceal rebleeding. J Hepatol (1998) 1.43
Identification of proteins encoded by a fragment of herpes simplex virus type 2 DNA that has transforming activity. J Virol (1982) 1.42
YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol (1995) 1.39
Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts. J Virol (1986) 1.39
Identification of the E5 open reading frame of human papillomavirus type 16. J Virol (1988) 1.38
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
Serum uric acid levels in patients with cirrhosis: a reevaluation. J Clin Gastroenterol (1999) 1.37
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia (2008) 1.36
Structure of the transforming region of human cytomegalovirus AD169. J Virol (1984) 1.35
Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures. Proc Natl Acad Sci U S A (1984) 1.34
Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem (1997) 1.33
Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology (1999) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol (1999) 1.32
Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res (1995) 1.32
Complete nucleotide sequence of the rabbit beta-like globin gene cluster. Analysis of intergenic sequences and comparison with the human beta-like globin gene cluster. J Mol Biol (1989) 1.30
Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol (1998) 1.28
Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology (1995) 1.28
Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis (1989) 1.26
YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol (1997) 1.25
HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology (1993) 1.25
Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology (1994) 1.24
Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol (1998) 1.24
Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology (1995) 1.21
Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol (1989) 1.20
First light-emitting neutral molecular rectangles. Inorg Chem (2000) 1.19
Concentric tracheal and subglottic stenosis. Management using the Nd-YAG laser for mucosal sparing followed by gentle dilatation. Chest (1993) 1.18
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia (2011) 1.18
The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol (1999) 1.18
Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol (1992) 1.18
The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev (1996) 1.17
Comparison of adrenaline injection and bipolar electrocoagulation for the arrest of peptic ulcer bleeding. Gut (1999) 1.17
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A (2001) 1.17
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol (2005) 1.17